Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ACYW135 Meningococcal Conjugate Vaccine (CRM197)-Sinovac Life Sciences Co., Ltd.-meningococcal meningitis
- Development stage
- Preclinical
- Lead developer
- Sinovac Life Sciences
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
An investigational **quadrivalent meningococcal conjugate vaccine** attributed in the supplied records to Sinovac Life Sciences for prevention of meningococcal disease/meningococcal meningitis caused by *Neisseria meningitidis* serogroups A, C, Y, and W-135. The intended mechanism is active immunization: capsular polysaccharide antigens conjugated to a carrier protein are designed to induce bactericidal anti-capsular antibodies and immunologic memory. However, the exact Sinovac product identity remains unresolved: Sinovac's publicly registered Phase Ia study identifies a **Group ACYW135X Meningococcal Conjugate Vaccine**, whereas the CRM197-carrier ACYW135 vaccine is explicitly identified as a CanSino comparator in related Sinovac Phase III records. Therefore, this annotation does not equate the requested Sinovac entry with CanSino's CRM197 product. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07374510?viewType=Table))
- Other names
- Group ACYW135 meningococcal conjugate vaccine
02
Targets
TCR (CD4+ T-cell receptor)Neisseria meningitidis group C capsular polysaccharideMCV (Meningococcal capsular polysaccharide-protein conjugate)CD14 (Monocyte differentiation antigen CD14)MenW CPS (Neisseria meningitidis serogroup W capsular polysaccharide)NmA CPS (Neisseria meningitidis group A capsular polysaccharide)Group Y CPS (Neisseria meningitidis group Y capsular polysaccharide)
Beyond the preview
Go deeper on ACYW135 Meningococcal Conjugate Vaccine (CRM197)-Sinovac Life Sciences Co., Ltd.-meningococcal meningitis.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ACYW135 Meningococcal Conjugate Vaccine (CRM197)-Sinovac Life Sciences Co., Ltd.-meningococcal meningitis.